ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Incidence of LV dysfunction with chemotherapy drugs

Incidence of LV dysfunction with chemotherapy drugs
Chemotherapy agents Incidence of heart failure (%) Incidence of decline in LVEF (%) 
Anthracyclines (cumulative dose)  
Doxorubicin (Adriamycin)  
 100  0  0.5
 150 mg/m2  0.2  7
 300 mg/m2  0.6  16
400 mg/m2 3 to 5  32
550 mg/m2 7 to 26  65
700 mg/m2 18 to 48  86
Idarubicin (>90 mg/m2) 5 to 18  
Epirubicin (>900 mg/m2) 0.9 to 11.4  
Mitoxantrone (>120 mg/m2) 2.6  
Liposomal anthracyclines (>900 mg/m2) 2  
LVEF: left ventricular ejection fraction. Decline in LVEF is defined as a decline in absolute value of at least 20 percent in LVEF from baseline, a decline in absolute value of at least 10 percent in LVEF from baseline and to below the institution's lower limit of normal, a postbaseline decline in absolute value of at least 5 percet in LVEF below the institution's lower limit of normal, or the occurrence of heart failure.
Data from:
  1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:2768.
  2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003; 97:2869.
Graphic 109645 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟